Simply Wall St.
Is West Pharmaceutical Services (WST) Pricing Too Much Growth Into Its Current Share Price?
📉
AI Sentiment
Negative
2/10
- Home
- WST
as of 03-04-2026 3:39pm EST
$250.46
$0.92
-0.37%
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | EXTON |
| Market Cap: | 16.6B | IPO Year: | 2004 |
| Target Price: | $319.43 | AVG Volume (30 days): | 915.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 6.79 | EPS Growth: | 1.49 |
| 52 Week Low/High: | $187.43 - $322.34 | Next Earning Date: | 05-15-2026 |
| Revenue: | $2,886,900,000 | Revenue Growth: | 1.95% |
| Revenue Growth (this year): | 6.73% | Revenue Growth (next year): | 6.07% |
| P/E Ratio: | 36.96 | Index: | |
| Free Cash Flow: | 468.9M | FCF Growth: | +69.64% |
AI-Powered WST Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.25%
71.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 12, 2026 · 100% conf.
AI Prediction SELL
1D
-2.11%
$238.46
5D
-6.43%
$227.95
20D
-4.35%
$233.01
Price: $243.61 Prob +5D: 0% AUC: 1.000
0000105770-26-000005
wst-202602120000105770false00001057702026-02-122026-02-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – February 12, 2026
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 1-8036 23-1210010
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA 19341-1147
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 610-594-2900 Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its fourth-quarter and full year 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing. Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated February 12, 2026.
99.2 West Pharmaceutical Services, Inc. Presentation, dated February 12, 2026.
104 The cover page from the Company’s Current Report on Form 8-K, dated February 12, 2026, formatted in Inline XBRL.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
/s/ Robert W. McMahon
Robert W. McMahon Senior Vice President, Chief Financial Officer
February 12, 2026
3
EXHIBIT INDEX
Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated February 12, 2026.
99.2 West Pharmaceutical Services, Inc. Presentation, dated February 12, 2026.
104 The cover page from the Company’s Current Report on Form 8-K, dated February 12, 2026, formatted in Inline XBRL.
4
2025 Q3 Q3 2025 Earnings
8-K Oct 23, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 23, 2025
0000105770-25-000090
wst-202510230000105770false00001057702025-10-232025-10-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – October 23, 2025
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 1-8036 23-1210010
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA 19341-1147
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 610-594-2900 Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition. On October 23, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its third-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing. Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
/s/ Robert W. McMahon
Robert W. McMahon Senior Vice President, Chief Financial Officer
October 23, 2025
3
EXHIBIT INDEX
Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL.
4
2025 Q2 Q2 2025 Earnings
8-K Jul 24, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 24, 2025
0000105770-25-000062
wst-202507240000105770false00001057702025-07-242025-07-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – July 24, 2025
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 1-8036 23-1210010
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA 19341-1147
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 610-594-2900 Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition.
On July 24, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its second-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.
A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated July 24, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated July 24, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated July 24, 2025, formatted in Inline XBRL.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
/s/ Bernard J. Birkett
Bernard J. Birkett Senior Vice President, Chief Financial Officer
July 24, 2025
3
EXHIBIT INDEX
Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated July 24, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated July 24, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated July 24, 2025, formatted in Inline XBRL.
4
Latest West Pharmaceutical Services Inc. News
WST Breaking Stock News: Dive into WST Ticker-Specific Updates for Smart Investing
Simply Wall St.
Why West Pharmaceutical (WST) Is Up 5.5% After New US$1 Billion Buyback And Dividend Increase
📈
AI Sentiment
Highly Positive
8/10
Compare WST vs Leading Stocks
See how WST stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "WST West Pharmaceutical Services Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.